FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892291622> ?p ?o ?g. }

• W2892291622 endingPage "37" @default.
• W2892291622 startingPage "30" @default.
• W2892291622 abstract "Ototoxicity is a health problem appearing after powerful treatments in serious health conditions. It is sometimes inevitable when treatment of the serious disease is required. Cisplatin is an antineoplastic agent which was investigated previously to reveal increased nitrogen and reactive oxygen radicals that damages hair cells, resulting in ototoxicity. N-acetylcysteine, previously shown to decrease ototoxicity caused by different agents, is known to be a powerful in vitro antioxidant. Probably N-acetylcysteine, in addition to its antioxidant effect, blocks a cascade where reactive oxygen species result in apoptosis in the cochlea. The possible preventive effect of N-acetylcysteine in cisplatin ototoxicity was studied with auditory brain stem responses, otoacoustic emissions, and histopathological investigation of the cochlea in a scanning electron microscopy. This study was conducted on 21 Wistar Albino rats in four groups. 1 mL/kg/day three times in total intraperitoneal (i.p.) Saline (n = 5), 500 mg/kg/day i.p. three times in total N-acetylcysteine (n = 5), i.p. 15 mg/kg cisplatin alone (single dose) (n = 5) and i.p. 15 mg/kg cisplatin plus 500 mg/kg/day N-acetylcysteine (n = 6) were administered. The rats were anesthetized to study the hearing tests before and after the experiment. The rats were sacrificed to investigate the cochleas by scanning electron microscopy. Auditory brain stem responses and otoacoustic emissions values were attenuated in the cisplatin group. The group that received N-acetylcysteine in addition to cisplatin had better auditory brain stem responses thresholds and otoacoustic emissions. The samples obtained from the cisplatin group showed surface irregularities, degeneration areas, and total or partial severe stereocilia losses. The changes were milder in the cisplatin + N-acetylcysteine group. Cisplatin ototoxicity can be detected by auditory brain stem responses and otoacoustic emissions testing in rats. N-acetylcysteine may protect the cochlear cells from histopathological changes. We concluded that N-acetylcysteine given 4 h after cisplatin injection has a potential otoprotective effect against cisplatin ototoxicity. which suggests it could be used in clinical trials. A ototoxicidade é um problema que pode ocorrer após certos tipos de tratamentos para condições graves de saúde. Às vezes é inevitável quando o tratamento da doença é necessário. A cisplatina é um agente antineoplásico cujo uso em pesquisas anteriores demonstrou aumentar os radicais livres de nitrogênio e espécies reativas de oxigênio que danificam as células ciliadas e resultam em ototoxicidade. Por outro lado, a N-acetilcisteína, que já demonstrou diminuir a ototoxicidade causada por diferentes agentes, é conhecida por ser um potente antioxidante in vitro. Provavelmente a N-acetilcisteína, além de seu efeito antioxidante, bloqueia uma cascata onde espécies reativas de oxigênio resultam em apoptose na cóclea. Estudar o possível efeito preventivo da N-acetilcisteína na ototoxicidade por cisplatina por meio de potencial evocado auditivo de tronco encefálico, emissões otoacústicas e investigação histopatológica da cóclea por microscopia eletrônica de varredura. Este estudo foi realizado em 21 ratos albinos Wistar, separados em quatro grupos. Foram administrados: 1 mL/kg/dia intraperitoneal (i.p.) de solução salina (n = 5), três vezes no total; 500 mg/kg/dia i.p. de N-acetilcisteína (n = 5), três vezes no total; 15 mg/kg i.p. (dose única) somente de cisplatina (n = 5) e 15 mg/kg i.p. de cisplatina e 500 mg/kg/dia i.p. de N-acetilcisteína (n = 6). Os ratos foram anestesiados para estudo dos testes auditivos antes e depois do experimento. Os ratos foram sacrificados para investigação da cóclea por microscopia eletrônica de varredura. Os potenciais evocados auditivos de tronco encefálico e os valores das emissões otoacústicas estavam atenuados no grupo cisplatina. O grupo que recebeu N-acetilcisteína além da cisplatina apresentou melhores limiares de respostas auditivas do tronco encefálico e emissões otoacústicas. As amostras obtidas do grupo cisplatina apresentaram irregularidades de superfície, áreas de degeneração, com perdas graves totais ou parciais de estereocílios. As alterações foram mais leves no grupo cisplatina + N-acetilcisteína. A ototoxicidade por cisplatina pode ser detectada por meio de potenciais evocados auditivos de tronco encefálico e pelo teste de emissões otoacústicas em ratos. A N-acetilcisteína pode proteger as células cocleares contra alterações histopatológicas. Concluímos que a N-acetilcisteína administrada 4 horas após a injeção de cisplatina tem potencial efeito otoprotetor contra a ototoxicidade por cisplatina e pode ser utilizada em ensaios clínicos." @default.
• W2892291622 created "2018-09-27" @default.
• W2892291622 creator A5006150751 @default.
• W2892291622 creator A5019365500 @default.
• W2892291622 creator A5021563008 @default.
• W2892291622 creator A5043874214 @default.
• W2892291622 creator A5064961016 @default.
• W2892291622 creator A5069544151 @default.
• W2892291622 date "2020-01-01" @default.
• W2892291622 modified "2023-10-18" @default.
• W2892291622 title "Protective effect of N-acetylcysteine against cisplatin ototoxicity in rats: a study with hearing tests and scanning electron microscopy" @default.
• W2892291622 cites W1045245205 @default.
• W2892291622 cites W146410082 @default.
• W2892291622 cites W150292688 @default.
• W2892291622 cites W194858676 @default.
• W2892291622 cites W1974768240 @default.
• W2892291622 cites W1981262221 @default.
• W2892291622 cites W2002071731 @default.
• W2892291622 cites W2005515353 @default.
• W2892291622 cites W2019202778 @default.
• W2892291622 cites W2026413105 @default.
• W2892291622 cites W2028324251 @default.
• W2892291622 cites W2031086138 @default.
• W2892291622 cites W2032662269 @default.
• W2892291622 cites W2037202852 @default.
• W2892291622 cites W2045181147 @default.
• W2892291622 cites W2046998793 @default.
• W2892291622 cites W2057029719 @default.
• W2892291622 cites W2070195200 @default.
• W2892291622 cites W2079399225 @default.
• W2892291622 cites W2082313150 @default.
• W2892291622 cites W2088276937 @default.
• W2892291622 cites W2103255849 @default.
• W2892291622 cites W2105275024 @default.
• W2892291622 cites W2105296692 @default.
• W2892291622 cites W2129630299 @default.
• W2892291622 cites W2131260008 @default.
• W2892291622 cites W2153844900 @default.
• W2892291622 cites W2164370509 @default.
• W2892291622 cites W2168846709 @default.
• W2892291622 cites W2338517088 @default.
• W2892291622 cites W236135089 @default.
• W2892291622 cites W4250415733 @default.
• W2892291622 doi "https://doi.org/10.1016/j.bjorl.2018.08.002" @default.
• W2892291622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268784" @default.
• W2892291622 hasPublicationYear "2020" @default.
• W2892291622 type Work @default.
• W2892291622 sameAs 2892291622 @default.
• W2892291622 citedByCount "14" @default.
• W2892291622 countsByYear W28922916222020 @default.
• W2892291622 countsByYear W28922916222021 @default.
• W2892291622 countsByYear W28922916222022 @default.
• W2892291622 countsByYear W28922916222023 @default.
• W2892291622 crossrefType "journal-article" @default.
• W2892291622 hasAuthorship W2892291622A5006150751 @default.
• W2892291622 hasAuthorship W2892291622A5019365500 @default.
• W2892291622 hasAuthorship W2892291622A5021563008 @default.
• W2892291622 hasAuthorship W2892291622A5043874214 @default.
• W2892291622 hasAuthorship W2892291622A5064961016 @default.
• W2892291622 hasAuthorship W2892291622A5069544151 @default.
• W2892291622 hasBestOaLocation W28922916221 @default.
• W2892291622 hasConcept C126322002 @default.
• W2892291622 hasConcept C185592680 @default.
• W2892291622 hasConcept C2776694085 @default.
• W2892291622 hasConcept C2777847592 @default.
• W2892291622 hasConcept C2778004101 @default.
• W2892291622 hasConcept C2778239845 @default.
• W2892291622 hasConcept C2778534666 @default.
• W2892291622 hasConcept C2779491297 @default.
• W2892291622 hasConcept C2780130748 @default.
• W2892291622 hasConcept C29730261 @default.
• W2892291622 hasConcept C42219234 @default.
• W2892291622 hasConcept C48349386 @default.
• W2892291622 hasConcept C548259974 @default.
• W2892291622 hasConcept C55493867 @default.
• W2892291622 hasConcept C71924100 @default.
• W2892291622 hasConcept C98274493 @default.
• W2892291622 hasConceptScore W2892291622C126322002 @default.
• W2892291622 hasConceptScore W2892291622C185592680 @default.
• W2892291622 hasConceptScore W2892291622C2776694085 @default.
• W2892291622 hasConceptScore W2892291622C2777847592 @default.
• W2892291622 hasConceptScore W2892291622C2778004101 @default.
• W2892291622 hasConceptScore W2892291622C2778239845 @default.
• W2892291622 hasConceptScore W2892291622C2778534666 @default.
• W2892291622 hasConceptScore W2892291622C2779491297 @default.
• W2892291622 hasConceptScore W2892291622C2780130748 @default.
• W2892291622 hasConceptScore W2892291622C29730261 @default.
• W2892291622 hasConceptScore W2892291622C42219234 @default.
• W2892291622 hasConceptScore W2892291622C48349386 @default.
• W2892291622 hasConceptScore W2892291622C548259974 @default.
• W2892291622 hasConceptScore W2892291622C55493867 @default.
• W2892291622 hasConceptScore W2892291622C71924100 @default.
• W2892291622 hasConceptScore W2892291622C98274493 @default.
• W2892291622 hasIssue "1" @default.
• W2892291622 hasLocation W28922916221 @default.
• W2892291622 hasLocation W28922916222 @default.
• W2892291622 hasLocation W28922916223 @default.
• W2892291622 hasOpenAccess W2892291622 @default.

• next